Spektus is a development focused pharma company with a focus on the global CNS segment. We leverage our patented drug delivery technologies to unlock clinically meaningful value and untapped potential in well-established drugs. Our team designs, formulates and develops these differentiated medicines that are approved via the 505b2 or similar regulatory pathways and are launched via a network of commercial partners across the globe.
Spektus is a joint venture combining the commercial acumen of Spektar Therapeutics with the pharmaceutical expertise of Altus Formulation.
